Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours

Correspondence to: Dr J Ramage, North Hampshire Hospital, Aldermaston Road, Basingstoke, Hants, UK; johnramage1@ compuserve.com . . . . . . . . . . . . . . . . . . . . . . . 1.0 SUMMARY OF RECOMMENDATIONS 1.1 Genetics N Clinical examination to exclude complex cancer syndromes (for example, multiple endocrine neoplasia 1 (MEN1)) should be performed in all cases of neuroendocrine tumours (NETs), and a family history taken (grade C). N In all cases where there is a family history of carcinoids or NET, or a second endocrine tumour, a familial syndrome should be suspected (grade C). N Individuals with sporadic or familial bronchial or gastric carcinoid should have a family history evaluation and consideration of testing for germline MEN1 mutations. Management of MEN1 families includes screening for endocrine parathyroid and enteropancreatic tumours from late childhood, with predictive testing for first degree relatives of known mutation carriers (grade C). N All patients should be evaluated for second endocrine tumours and possibly for other gut cancers (grade C)